Bringing a new drug to market is a long and costly journey. From early discovery to launch, development typically takes 10 to 15 years, with total costs often exceeding USD 2 billion once failures are factored in. By the time a product finally reaches patients, only eight to ten years of market exclusivity may remain. This places intense pressure on pricing, returns, and long‑term viability.
At the same time, pharmaceutical companies face growing expectations from governments, insurers, patients, and advocacy groups. There is strong demand for faster access to affordable medicines, particularly in areas of unmet medical need. Against this backdrop, accelerating development timelines is no longer a competitive advantage. It is a necessity.
Cutting even two or three years from development can make a substantial difference. It reduces costs and extends the effective period of patent protection, creating more time to recover investment once a product is launched. The question is no longer whether development can be accelerated, but how.
The record‑breaking approvals of COVID‑19 vaccines and therapeutics offered a powerful proof point. While these were exceptional cases, they demonstrated that regulatory‑compliant development at speed is possible when processes, data, and collaboration are aligned.
Just as importantly, they highlighted where time and cost savings can be achieved across the broader development lifecycle, from discovery through clinical trials and into manufacturing.
One of the most significant enablers of faster development is artificial intelligence. Its impact is already being felt at multiple stages.
In early discovery, in silico predictive modelling is improving the identification of promising drug candidates. At the same time, AI‑driven insights into ADME and toxicity are helping to raise the overall quality of assets entering the pipeline. This reduces downstream attrition and shortens timelines from the very start.
Clinical trials, often the longest phase of development, also stand to benefit. Delays in patient recruitment remain a common bottleneck, and AI can help by identifying suitable patient populations in the right locations. It also supports adaptive trial designs, enabling protocol adjustments without unnecessary disruption.
Beyond the clinic, CMC (chemistry, manufacturing and controls) is another area where computational approaches are delivering tangible gains. Advanced simulations can significantly accelerate process development and are increasingly accepted by regulators as part of the overall data package.
At the heart of any successful acceleration strategy lies Quality by Design (QbD). By using statistically planned design of experiments, teams can rapidly explore a process’s design space and gain deep understanding with fewer, more informative experiments.
When combined with process analytical technology, this approach enables continuous monitoring and rich data generation. In many cases, just three to five well‑designed experiments are sufficient to build a robust in silico model that supports faster and more reliable scale‑up. Any remaining issues can then be addressed through targeted troubleshooting, rather than prolonged trial‑and‑error.
Not every process can be fully digitized. For complex reactions, such as multi‑phase systems, physical downscaled reactor models, often supported by 3D printing, provide an effective alternative. While slightly slower than purely computational methods, this approach still delivers significant time savings compared with traditional development routes.
Crucially, data collection does not stop once production begins. Information from manufacturing runs can be used to monitor deviations and even support predictive maintenance, further improving robustness and efficiency over time.
Accelerated development places greater demands on coordination and communication, particularly when multiple activities are running in parallel. This is especially true during tech transfer and scale‑up, where manufacturing and regulatory teams must work in close alignment.
Scientific excellence and regulatory excellence are deeply interconnected. When these functions collaborate effectively, clinical trial supplies can be made available earlier, without compromising quality or compliance.
At Siegfried, there is a growing trend for client processes to arrive less mature, as projects are pushed forward rapidly. This often results in development work being carried out simultaneously in client laboratories and at Siegfried sites. To succeed under these conditions, teams need comparable equipment, seamless data transfer, and rigorous analytical scrutiny to ensure quality is maintained throughout.
While speeding up individual workstreams delivers value, the greatest gains come from bringing everything together coherently. Digital tools and platforms can help parallelize activities, but real acceleration depends on trust between all parties involved. This is particularly true for collaborations between pharmaceutical companies and CDMOs such as Siegfried. Accelerated development inevitably involves a degree of risk, and long term partnerships provide the foundation needed to manage that risk effectively. When trust is in place, timelines shorten, decisions improve, and patients ultimately benefit sooner.
If you are interested in learning more about the Siegfried and its capabilities, contact us: